Ensysce Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENSC research report →
Price Chart
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology.
- CEO
- D. Lynn Kirkpatrick
- IPO
- 2018
- Employees
- 9
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on ENSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.00M
- P/E
- -0.06
- PEG
- 0.00
- P/S
- 1.34
- P/B
- 0.24
- EV/EBITDA
- 1.96
- Div Yield
- 0.00%
- Gross Margin
- 99.88%
- Op Margin
- -220.14%
- Net Margin
- -1740.69%
- ROE
- -1232.64%
- ROIC
- -42.21%
Latest fiscal year · YoY change
- Revenue
- $5.07M+0.0%
- Gross Profit
- $5.07M+0.0%
- Op Income
- $-10,240,946
- Net Income
- $-10,176,187-27.4%
- EPS
- $-3.98+12.9%
- OCF Growth
- -4.0%
- FCF Growth
- -5.7%
- 52W High
- $1.85
- 52W Low
- $0.23
- 50D MA
- $0.44
- 200D MA
- $0.40
- Beta
- 1.09
- RSI (14)
- 40
- Avg Volume
- 504.35K
No earnings-call transcripts are available for ENSC yet.
- Free Float
- 95.3%
- Shares Outstanding
- 19.46M
- Float Shares
- 18.54M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Covington Capital Management | 100 | 0 |
Held by 5 ETFs
Biggest fund positions in ENSC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 7, 26 | GOWER BOB G | buy | 400,000 |
| Apr 23, 26 | GOWER BOB G | buy | 508,614 |
| Apr 23, 26 | GOWER BOB G | other | 254,307 |
| Aug 5, 26 | Morrison James William | other | 0 |
| Mar 2, 23 | GOWER BOB G | buy | 90,287 |
| Mar 1, 23 | GOWER BOB G | buy | 270,000 |
| Feb 28, 23 | GOWER BOB G | buy | 109,300 |
| Dec 9, 22 | GOWER BOB G | buy | 357,143 |
| Dec 9, 22 | GOWER BOB G | other | 714,286 |
| Jun 23, 22 | Chang William H | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENSC coverage
Recent articles, reports, and earnings notes.
No research on ENSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENSC report →Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
accessnewswire.com · Oct 21
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)
defenseworld.net · Sep 29
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
accessnewswire.com · Sep 24
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
accessnewswire.com · Sep 15
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
accessnewswire.com · Sep 14
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
accessnewswire.com · Sep 2
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
accessnewswire.com · Aug 31
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
accessnewswire.com · Aug 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.